Dechert LLP advised Medtech SA, and the main selling stockholders, Bertin Nahum, Newfund and Ally Bridge Group on the disposition to Zimmer Biomet. Medtech, founded in 2002, designs, develops, and markets robotic for brain surgery Rosa and applications to assist in surgical procedures, helping to create safer and more efficient, less invasive treatment.

Zimmer Biomet, a global leader in musculoskeletal healthcare, acquired 1,406,151 Medtech shares in the transaction, each share acquired at €50.00. The convertible bonds were acquired at a price of €50.03 per convertible bond and the warrants at a price of €17.17 per warrant. As part of the transaction, Zimmer Biomet will continue to maintain operations of Medtech in Montpellier, France.

The Dechert team advising the stockholders was led by corporate partner Matthieu Grollemund assisted by:

* Charles Cardon, national partner, Quentin Durand and Raphaël Sendowski, associates, on corporate aspects;
* Marianne Schaffner, partner, on Intellectual Property aspects;
* Mélanie Thill-Tayara, partner, on Antitrust/Competition aspects;
* Bruno Leroy, partner, on Tax aspects;
* Phillipe Thomas, Thomas Johnson (based in Philadelphia), partners, and Thibault Meiers, associate, on Employment aspects.